Bio-Path Holdings (BPTH)
(Delayed Data from NSDQ)
$2.34 USD
+0.10 (4.46%)
Updated May 16, 2024 04:00 PM ET
After-Market: $2.34 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BPTH 2.34 +0.10(4.46%)
Will BPTH be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BPTH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BPTH
Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study
BPTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for BPTH
Bio-Path Holdings Inc (BPTH) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ...
Bio-Path Holdings Inc. (BPTH) Q1 2024 Earnings Call Transcript
BPTH Stock Earnings: Bio-Path Holdings Misses EPS for Q1 2024
Bio-Path: Q1 Earnings Snapshot
Bio-Path Holdings Reports First Quarter 2024 Financial Results